In last trading session, Dianthus Therapeutics Inc (NASDAQ:DNTH) saw 0.79 million shares changing hands with its beta currently measuring 1.38. Company’s recent per share price level of $17.63 trading at -$0.5 or -2.76% at ring of the bell on the day assigns it a market valuation of $566.98M. That closing price of DNTH’s stock is at a discount of -83.04% from its 52-week high price of $32.27 and is indicating a premium of 24.22% from its 52-week low price of $13.36. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.29 million shares which gives us an average trading volume of 312.79K if we extend that period to 3-months.
For Dianthus Therapeutics Inc (DNTH), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.17. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
Upright in the red during last session for losing -2.76%, in the last five days DNTH remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $17.63 price level, adding 5.52% to its value on the day. Dianthus Therapeutics Inc’s shares saw a change of -27.27% in year-to-date performance and have moved 4.60% in past 5-day. Dianthus Therapeutics Inc (NASDAQ:DNTH) showed a performance of -0.28% in past 30-days. Number of shares sold short was 6.69 million shares which calculate 23.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 51.5 to the stock, which implies a rise of 65.77% to its current value. Analysts have been projecting 51 as a low price target for the stock while placing it at a high target of 52. It follows that stock’s current price would drop -189.28% in reaching the projected high whereas dropping to the targeted low would mean a loss of -189.28% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 40.14% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -31.11% while estimates for its earnings growth in next 5 years are of -16.60%.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
Insiders are in possession of 7.87% of company’s total shares while institution are holding 119.90 percent of that, with stock having share float percentage of 130.14%. Investors also watch the number of corporate investors in a company very closely, which is 119.90% institutions for Dianthus Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at DNTH for having 4.4 million shares of worth $113.93 million. And as of 2024-06-30, it was holding 12.8624 of the company’s outstanding shares.
The second largest institutional holder is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, which was holding about 3.01 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8042 of outstanding shares, having a total worth of $77.99 million.
